Biotech Values

[dewophile]

It’s curious that the first CVR payout is triggered by enrollment of the fifth patient in the BLU-808 phase-2b/phase-3 trial. This gives SNY an opening to enroll three or four patients and then halt the trial for (alleged) safety reasons.

THRD's first drug got into liver tox issues only after 8 weeks or so of dosing. There was zero signal in the HV trial (I think it went 2 weeks). They claim this was due to accumulation of a toxic metabolite. So it was halted after like 3-4 patients were dosed. So this might explain this odd trigger for the CVR.
FWIW THRD made a point of saying their follow on drug doesn't have this issue preclinically, as has ENTA

No GSH adducts (or reactive metabolites) detected in vitro or in vivo

.
https://ir.enanta.com/static-files/0b9a9564-339c-4501-8c98-eab636846bf4

BPMC AFAIK has never mentioned anything about it